对于酒精使用障碍的重新使用塞马格卢提德和利拉格卢提德
Markku Lähteenvuo1, Jari Tiihonen1,2,3, Anssi Solismaa4,5
1Department of Forensic Psychiatry, University of Eastern Finland, Niuvanniemi Hospital, Kuopio, Finland.
JAMA psychiatry
|November 13, 2024
概括
葡萄糖类-1 (GLP-1) 激动剂,如西马格卢提德和利拉格卢提德,在瑞典的一项大型研究中显著减少了酒精使用障碍 (AUD) 的住院治疗. 这些发现表明GLP-1激动剂可能为AUD提供新的治疗途径.
科学领域:
- 内分泌学 在内分泌学.
- 精神病学是一个精神病学.
- 公共卫生 公共卫生
背景情况:
- 葡萄糖类-1 (GLP-1) 受体激活剂已成为2型糖尿病和肥胖症的治疗方法.
- 初步证据表明GLP-1激动剂可能会降低酒精消耗.
- 酒精使用障碍 (AUD) 构成重大公共卫生负担,需要新的治疗策略.
研究的目的:
- 调查GLP-1激动剂使用与因酒精使用障碍 (AUD) 入院的风险之间的关联.
- 为了比较同一个人中的GLP-1主激素使用者与非使用者之间AUD住院的风险.
- 评估二次结果,包括物质使用障碍 (SUD) 住院,体质住院和自杀企图.
主要方法:
- 在瑞典进行的一项全国性基于人口的队列研究 (2006-2023) 确定了16-64岁的AUD诊断的个人.
- 数据来源于瑞典国家登记册,包括住院护理,门诊护理,病假和残疾养老金.
- 采用个人内部的考克斯回归模型来分析初级暴露 (GLP-1激动剂使用与不使用) 和初级结局 (AUD住院).
主要成果:
- 这项研究包括227,866名患有AUD的个人. 塞马格卢提德的使用与AUD住院 (aHR,0.64) 和任何SUD住院 (aHR,0.68) 的最低风险有关.
- 利拉格卢提德的使用显示了AUD住院的第二低风险 (aHR,0.72) 和任何SUD住院的风险 (aHR,0.78).
- GLP-1激动剂也与体质住院减少有关,但没有自杀企图. 使用已批准的AUD药物显示了适度的风险降低 (aHR,0.98).
结论:
- 在AUD患者中,特别是那些患有并发性肥胖或2型糖尿病的患者中,塞马格卢提德和利拉格卢提德与AUD相关住院病例的大幅减少有关.
- 观测到的风险降低与semaglutide和liraglutide超过了官方批准的AUD药物.
- 这些发现突显了塞马格卢提德和利拉格卢提德在治疗AUD方面的潜在疗效,需要紧急进行临床试验以确认.
更多相关视频
相关概念视频
Drugs for Treatment of Diarrhea-Predominant IBS
147
Diarrhea-predominant irritable bowel syndrome (IBS-D) is a subtype of IBS characterized primarily by frequent, loose, or watery stools, abdominal pain, and abdominal discomfort. Therapeutic approaches to managing IBS-D include dietary changes, stress management techniques, and pharmaceutical interventions.
Two specific drugs used in the treatment are alosetron (Lotronex) and eluxadoline (Viberzi). Alosetron, a 5-HT3 antagonist, works by slowing the movement of stools in the gut, reducing bowel...
Two specific drugs used in the treatment are alosetron (Lotronex) and eluxadoline (Viberzi). Alosetron, a 5-HT3 antagonist, works by slowing the movement of stools in the gut, reducing bowel...
147
CNS Depressants: Alcohol and Nicotine
174
Ethanol, a clear colorless alcohol, has been consumed by humans for millennia, but its effects on the body are far from benign. At lower doses, it induces decreased inhibitions and loquaciousness, leading to its social appeal. However, it can cause severe consequences at higher doses, such as coma and respiratory depression, due to its zero-order elimination kinetics. Chronic ethanol abuse wreaks havoc on multiple organ systems, particularly the CNS and the liver. Abrupt cessation of ethanol...
174
Oral Hypoglycemic Agents: α-Glucosidase Inhibitors
159
α-glucosidase inhibitors, including acarbose (Precose), miglitol (Glyset), and voglibose (Voglib) (primarily available in Asia), are drugs that control blood sugar levels by delaying the digestion of starch and disaccharides. They achieve this by inhibiting α-glucosidase enzymes in the intestine, which slow the absorption of carbohydrates in the intestine, which in turn leads to a prolonged release of the glucoregulatory hormone GLP-1 from intestinal L-cells.
Acarbose and miglitol are...
Acarbose and miglitol are...
159
Antidepressant Drugs: MAOIs and Other Agents
195
Atypical antidepressants, including bupropion (Wellbutrin), mirtazapine (Remeron), nefazodone (Serzone), trazodone (Desyrel), and vilazodone (Viibryd), offer unique mechanisms of action. Bupropion weakly inhibits dopamine and norepinephrine reuptake, aiding depression treatment and smoking cessation, with a low risk of sexual dysfunction. Mirtazapine enhances serotonin and norepinephrine neurotransmission, leading to sedation, increased appetite, and weight gain. As a result, it helps treat...
195
Dipeptidyl Peptidase 4 Inhibitors
172
Dipeptidyl peptidase 4 (DPP-4) is a serine protease widely distributed in the body. It's involved in the inactivation of GLP-1 and GIP hormones, which are crucial for insulin regulation. DPP-4 inhibitors, such as sitagliptin (Januvia), saxagliptin (Onglyza), linagliptin (Tradjenta), alogliptin (Nesina), and vildagliptin (Galvus), help increase the proportion of active GLP-1, enhancing insulin secretion. These inhibitors work by competitively binding to DPP-4. This binding causes a...
172


